Which companies overlap with Federation Francophone de Cancerologie Digestive's portfolio?

Top competitors by shared drug class: AstraZeneca, Sun Yat-sen University, Japan Clinical Oncology Group, Shanghai Junshi Bioscience Co., Ltd., Sixth Affiliated Hospital, Sun Yat-sen University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/federation-francophone-de-cancerologie-digestive.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Federation Francophone de Cancerologie Digestive — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Federation Francophone de Cancerologie Digestive pipeline: 1 marketed, 0 filed, 10 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 10 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Aflibercept Injection	Aflibercept Injection	marketed
FOLFOX4 or XELOX	FOLFOX4 or XELOX	phase 3	Combination chemotherapy (fluoropyrimidine + platinum agent)	Thymidylate synthase (5-FU/capecitabine); DNA (oxaliplatin cross-linking)	Oncology
liposomal cisplatin	liposomal cisplatin	phase 3	Platinum-based chemotherapy		Oncology
Oxaliplatin intra-arteriel	Oxaliplatin intra-arteriel	phase 3	Platinum-based chemotherapy agent	DNA (forms crosslinks)	Oncology
LV5FU2 or capecitabine	LV5FU2 or capecitabine	phase 3	Fluoropyrimidine antimetabolite	Thymidylate synthase	Oncology
Ipilimumab Injection	Ipilimumab Injection	phase 3	CTLA-4 inhibitor	CTLA-4	Oncology
LV5FU2 or capectitabine	LV5FU2 or capectitabine	phase 3	Fluoropyrimidine antimetabolite	Thymidylate synthase	Oncology
Oxaliplatin intravenous	Oxaliplatin intravenous	phase 3	Platinum-based chemotherapy agent	DNA	Oncology
radiochemotherapy	radiochemotherapy	phase 3			Other
Atezolizumab Injection	Atezolizumab Injection	phase 3	PD-L1 inhibitor	PD-L1	Oncology
induction chemotherapy (mDCF)	induction chemotherapy (mDCF)	phase 3	Combination chemotherapy regimen		Oncology

Therapeutic area mix

Oncology · 10
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 5 shared drug classes
Sun Yat-sen University · 5 shared drug classes
Japan Clinical Oncology Group · 3 shared drug classes
Shanghai Junshi Bioscience Co., Ltd. · 3 shared drug classes
Sixth Affiliated Hospital, Sun Yat-sen University · 3 shared drug classes
Hoffmann-La Roche · 3 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 3 shared drug classes
Taiho Pharmaceutical Co., Ltd. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Federation Francophone de Cancerologie Digestive:

Cite this brief

Drug Landscape (2026). Federation Francophone de Cancerologie Digestive — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/federation-francophone-de-cancerologie-digestive. Accessed 2026-05-17.